The Latest Breaking News from PFE

The Centers for Disease Control and Prevention recommended that children ages 5 to 11 receive the newly authorized COVID-19 booster shot from Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX). Following the recommendation, many of the nation's doctors, pharmacies, and other vaccination sites are expected to begin offering the extra doses to the 28 million U.S. children…

The U.S. National Institutes of Health and Pfizer Inc (NYSE:PFE) are discussing testing a longer course of COVID-19 antiviral treatment Paxlovid, required to prevent reinfections, White House Chief Medical Officer Anthony Fauci said. "We're going to be planning what studies we're going to be doing relatively soon, within the next few days," to…

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Wednesday marks the last chance for investors to receive the next dividend payout from Pfizer (NYSE:PFE).

Additional reports of patients with long COVID who were helped by Pfizer Inc's (NYSE: PFE) oral antiviral treatment Paxlovid have surfaced, providing momentum for conducting clinical trials to test the treatment, 

The FDA berates Pfizer Inc (NYSE: PFE) CEO Albert Bourla's proposed solution in cases where virus levels rebound after the first course of treatment.

The Fed's plan to raise interest rates aggressively has aggravated bearish investor sentiment ahead of the Federal Reserve Board meeting this week. And rising recessionary fears are expected to sustain the bearish mood in the near term. However, quality mega-cap stocks Abbott (ABT), Broadcom (AVGO), and Pfizer (PFE) are expected…

Pfizer Inc (NYSE:PFE) has reported a Q1 adjusted EPS of $1.62, up 72% Y/Y, well ahead of the consensus of $1.50.  The company achieved revenues of $25.66 billion, up 77%, beating the Wall Street estimate of $23.95 billion. Its COVID-19 vaccine, Comirnaty, contributed $13.2 billion in direct sales and alliance revenues. Eliquis…

The near-term market outlook remains cloudy. While the S&P 500 is about 3% above its late-February lows, the Nasdaq and Russell 2000 have already undercut these levels. Below are 3 such stocks that investors should consider buying during this market correction: Anthem (ANTM), Pfizer (PFE), and Builders FirstSource (BLDR).